Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Hematology Frontier

Home » Hematology Frontier » Page 3
ASH China Voice | Prof. Xiaoxia Hu / Dr. Zilu Zhang: IPSS-M and Conditioning Intensity in Transplant Decision-Making for MDS

ASH China Voice | Prof. Xiaoxia Hu / Dr. Zilu Zhang: IPSS-M and Conditioning Intensity in Transplant Decision-Making for MDS

Posted by By Peng Geng 2025.12.19
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option for patients with myelodysplastic syndromes (MDS). However, clinical decision-making in the transplant setting remains challenging. Two critical and unresolved issues…
Read More
News Bulletin · CML Highlights | Prof. Qian Jiang: Global Frontiers in CML and the Chinese Perspective

News Bulletin · CML Highlights | Prof. Qian Jiang: Global Frontiers in CML and the Chinese Perspective

Posted by By Peter W. PENG 2025.12.19
The 2025 Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9. As one of the world’s premier events in hematology, the…
Read More
ASH China Voice | Prof. Yi Luo & Lizhen Liu: Preemptive Ven+Aza Therapy Offers a New Strategy to Prevent Post-Transplant Relapse in AML/MDS

ASH China Voice | Prof. Yi Luo & Lizhen Liu: Preemptive Ven+Aza Therapy Offers a New Strategy to Prevent Post-Transplant Relapse in AML/MDS

Posted by By Mourabit Halima 2025.12.19
CAR-T cell therapy has achieved transformative success in lymphoid malignancies, yet its application in acute myeloid leukemia (AML) remains highly challenging. Against this backdrop, a sequential strategy integrating CD7-targeted CAR-T…
Read More
ASH China Voice | Prof. Yi Luo & Lizhen Liu: Preemptive Ven+Aza Opens a New Strategy to Prevent Post-Transplant Relapse in AML/MDS

ASH China Voice | Prof. Yi Luo & Lizhen Liu: Preemptive Ven+Aza Opens a New Strategy to Prevent Post-Transplant Relapse in AML/MDS

Posted by By Peng Longmei 2025.12.19
At a recent Annual Meeting of the American Society of Hematology (ASH), a prospective study conducted by Prof. Yi Luo’s team at The First Affiliated Hospital, Zhejiang University School of…
Read More
ASH China Voice | Prof. Rong Fu’s Team: Advances and Precision Treatment Strategies in AA, PNH, and MDS

ASH China Voice | Prof. Rong Fu’s Team: Advances and Precision Treatment Strategies in AA, PNH, and MDS

Posted by By Mourabit Halima 2025.12.19
December 6–9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential hematology conference, ASH annually…
Read More
ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies

ASH China Voice | Professors Lu Peihua / Zhang Xian: CD7 CAR-T Therapy Significantly Improves Outcomes in R/R CD7-Positive Hematologic Malignancies

Posted by By Peter W. PENG 2025.12.18
At the 67th Annual Meeting of the American Society of Hematology (ASH), Professor Lu Peihua and Professor Zhang Xian from Lu Daopei Hospital presented a large-scale clinical study of a…
Read More
ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification

ASH Hot Topics | Prof. Yang Linhua: Anti-BAFF-R mAb Advances ITP from Symptom Control to Disease Modification

Posted by By Mourabit Halima 2025.12.17
Immune thrombocytopenia (ITP) is an immune-mediated thrombocytopenic disorder that can lead to severe bleeding and markedly impair quality of life. At the 67th Annual Meeting of the American Society of…
Read More
ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

ASH Guideline Interpretation | Professor Duan Minghui: Key Highlights of the Myelofibrosis Clinical Practice Guidelines and Implications for China

Posted by By Mourabit Halima 2025.12.17
On December 6 (local time), a highly anticipated special session on the ASH Clinical Practice Guidelines on Myelofibrosis was successfully held during the American Society of Hematology (ASH) Annual Meeting.…
Read More
ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

ASH China Voices | Professors Lu Peihua, Yang Junfang, and He Jiujiang: Advances in CNS-Involved R/R T-ALL/LBL and NUP214::ABL1 Leukemia

Posted by By Peng Longmei 2025.12.17
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international…
Read More
ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

ASH China Voice | Professor Huang Haiwen: Clinical Value of CAR-T–Transplant Sequencing and the Pola-AR2 Regimen

Posted by By Mourabit Halima 2025.12.17
At this year’s Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang Haiwen from the First Affiliated Hospital of Soochow University reported multiple important…
Read More

Posts pagination

Previous page 1 2 3 4 5 … 20 Next page
Recent Posts
  • ASH China Voice | Professor Cai Zhen: Multidimensional Exploration and Precision Breakthroughs in Multiple Myeloma — From Mechanistic Insights to Therapeutic Innovation 
  • ASH China Voice | Professor Du Juan: First-Line BCMA/CD19 Dual-Target FasTCAR-T Redefines Outcomes for Patients with Newly Diagnosed Multiple Myeloma
  • ASH Voice from China丨Professor Hu Kai: Addressing Clinical Needs and FrontiersMultiple Advances in CAR-T Cell Therapy for Relapsed/Refractory Lymphoma
  • Professor Zhisong He: Advances and Unresolved Challenges in the Treatment of Non–Muscle-Invasive Bladder Cancer
  • Professor Liqun Zhou: Standardized Development and Future Perspectives of Minimally Invasive Surgery for Urologic Tumors
Recent Comments
    Archives
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司(香港)
    Scroll to Top